University Of Mississippi

Greater adherence to TNF inhibitor therapy for rheumatoid arthritis led to fewer adverse events, with the optimal adherence threshold being approximately 60% of days covered, according to data published in Clinical Rheumatology.

Nearly one-quarter of outpatient visits by patients with systemic autoimmune rheumatic diseases in the United States between 2006 and 2019 resulted in an opioid prescription, according to data published in Arthritis Care & Research.

Semaglutide was associated with improved HF symptoms and exercise capacity and reduced body weight and inflammation among patients with obesity across the range of HF with mildly reduced and preserved ejection fraction, a speaker reported.

SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.

Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.

Patiromer for prevention of hyperkalemia and maintenance of renin-angiotensin-aldosterone inhibitor use in patients with HF with reduced ejection fraction.

WASHINGTON — In this Healio video exclusive, Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, discusses the results of the DIAMOND trial of patiromer for the reduction of hyperkalemia in patients with HF with reduced ejection fraction.

WASHINGTON — Patiromer, a novel potassium binder, was associated with a reduction in hyperkalemia in patients with HF with reduced ejection fraction, enabling an increase in adherence to optimal medical therapy, researchers reported.

Referrals from primary care providers to Pediatric Mental Health Care Access programs rose and involved more complex mental health concerns during the COVID-19 pandemic, according to study results.

Compared with just a few years ago, medical treatment options for HF with preserved ejection fraction have expanded greatly, culminating in the first useful new agent for the HFpEF population.